EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%

被引：0
|
作者：
Rizvi, N. [1 ]
Lee, S. [2 ]
Curtis, P. [2 ]
Caldwell, W. [2 ]
Gao, B. [2 ]
Rietschel, P. [2 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Anti-PD-1; cemiplimab; REGN2810;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.04-26
引用
收藏
页码：S931 / S932
页数：2
相关论文
共 50 条
  • [1] EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S931
  • [2] Survival data from EMPOWER-Lung 4: Phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)
    Shim, B. Y.
    Lee, S.
    de Castro Carpeno, J.
    Chiu, C-H.
    Cobo, M.
    Kim, H. R.
    Ryu, J. S.
    Majem Tarruella, M.
    Summers, Y.
    Thomas, C. A.
    Xu, Y.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S760 - S760
  • [3] Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Ozguroglu, M.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Fuang, H. G.
    Kulyaba, Y.
    Zyuhal, K.
    Scheusan, R. I.
    Baramidze, A.
    Garassino, M. C.
    Li, Y.
    Jia, X.
    Kaul, M.
    Perez, J.
    Seebach, F.
    Lowy, I.
    Pouliot, J. F.
    Kim, E.
    Rietschel, P.
    Magnan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S35 - S35
  • [4] Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S125 - S126
  • [5] EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
    Gogishvili, M.
    Mobashery, N.
    Makharadze, T.
    Navarro, M.
    Snodgrass, P.
    Chen, H.
    Lowy, I.
    Rietschel, P.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S649 - S649
  • [6] A Phase 2/3 Study of Fianlimab plus Cemiplimab versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%
    Faulkner, Neil
    Nair, Santosh
    Gabrail, Nashat
    Kunta, Gopal
    Ibrahim, Emad
    Dreisbach, Luke
    Brungs, Daniel
    Mani, Jayakumar
    Ghattas, Maria
    Li, Siyu
    Salvati, Mark
    Lowy, Israel
    Hiley, Tara
    Fury, Matthew G.
    Paoluzzi, Luca
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E39 - E39
  • [7] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [8] Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3
    Baramidze, A.
    Gessner, C.
    Gogishvili, M.
    Sezer, A.
    Makharadze, T.
    Kilickap, S.
    Gumus, M.
    Li, Y.
    Li, S.
    Salvati, M.
    Pouliot, J. -F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S316 - S317
  • [9] Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
    Gumus, M.
    Kilickap, S.
    Sezer, A.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S321
  • [10] Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
    Gumus, Mahmut
    Chen, Chieh-I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345